Exagen Inc.

Name: Exagen Inc. standardized financial statements, quarterly
Creator: Listed

XGNNasdaqCIK 1274737HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$19.9m, Q2 FY2026

Operating income−$1.7m, Q2 FY2026

Net income−$3.2m, Q2 FY2026

Exagen Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	13.4	13.8	14.4	15.1	12.5	13.7	15.5	17.2	17.2	16.6	17.3	19.9
Cost of revenue	$m	5.7	5.6	5.8	6.0	5.5	5.2	6.4	6.8	7.2	7.4	7.1	7.7
Gross profit	$m	not reported	not reported	8.6	9.1	7.0	8.5	9.1	10.4	10.1	9.2	10.2	12.2
Research and development	$m	1.4	1.1	1.1	1.2	1.5	1.7	1.3	1.5	1.7	1.8	1.6	1.4
Selling, general and administrative	$m	11.4	12.2	10.5	10.5	10.2	10.2	11.2	11.5	11.4	12.4	12.1	12.5
Operating income	$m	(5.1)	(5.1)	(3.0)	(2.6)	(4.7)	(3.4)	(3.4)	(2.6)	(3.1)	(5.0)	(3.4)	(1.7)
Interest expense	$m	0.6	0.6	0.5	0.6	0.6	0.6	0.5	1.1	1.3	1.3	1.3	1.2
Income tax	$m	not reported	not reported	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(5.4)	(5.6)	(3.4)	(3.0)	(5.0)	(3.8)	(3.8)	(4.4)	(7.1)	(4.7)	(4.0)	(3.2)
Diluted EPS	$ per share	(0.31)	not reported	(0.19)	(0.16)	(0.28)	not reported	(0.20)	(0.21)	(0.31)	not reported	(0.17)	(0.13)
Basic EPS	$ per share	(0.31)	not reported	(0.19)	(0.16)	(0.28)	not reported	(0.20)	(0.21)	(0.31)	not reported	(0.17)	(0.13)

Balance sheet

Cash and equivalents$24.6m, Q2 FY2026

Long-term debt$22.3m, Q2 FY2026

Shareholders' equity$12.2m, Q2 FY2026

Exagen Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	28.4	36.5	27.3	24.5	22.0	22.0	11.2	30.0	35.7	32.2	21.5	24.6
Current assets	$m	48.9	47.8	42.4	40.8	35.6	36.5	32.5	51.0	52.6	48.9	43.6	42.9
Total assets	$m	60.9	56.9	50.8	49.3	43.6	44.7	40.3	58.8	62.8	58.0	52.0	51.9
Current liabilities	$m	10.1	11.9	8.8	9.4	8.8	13.5	14.0	10.3	12.9	14.2	12.6	13.5
Total liabilities	$m	33.4	34.3	30.8	31.7	30.7	35.1	33.9	37.7	44.7	40.6	37.5	39.7
Long-term debt	$m	19.2	19.2	19.3	19.8	19.8	19.8	18.4	22.3	22.3	22.3	22.3	22.3
Current portion of debt	$m	0.3	0.3	0.3	0.4	0.4	0.4	2.5	0.7	0.7	0.6	0.6	0.5
Shareholders' equity	$m	27.5	22.7	20.0	17.6	12.9	9.5	6.4	21.0	18.1	17.4	14.4	12.2

Cash flow

Operating cash flow$4.0m, Q2 FY2026

Capital expenditure$543.0k, Q2 FY2026

Exagen Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(2.9)	8.3	(9.0)	(2.4)	(2.2)	0.4	(10.7)	(2.9)	2.9	(3.0)	(10.4)	4.0
Capital expenditure	$m	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.0	0.2	0.5

Diluted shares (weighted)24.16m, Q2 FY2026

Exagen Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	17.1	17.5	17.7	17.7	17.9	18.2	18.3	18.6	21.1	22.9	23.9	24.2

Shares outstanding: 24.23m at Jul 30, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.